Soligenix Pioneers Immune-Modulating Therapy to Combat Antibiotic Resistance
June 30, 2025 — Soligenix Inc. advances SGX943, a novel therapy for antibiotic-resistant infections, and develops vaccines for COVID-19 and more, marking a leap in biopharmaceutical innovation.